Risk factors for infection in patients with SLE receiving IV-CYC
| Univariate analysis | Multivariate analysis | ||||
| With infection (n=177) | Without infection (n=845) | P value | OR (95% CI) | P value | |
| Age, years | 36.00 (29.00–50.00) | 39.00 (30.00–50.00) | 0.161 | ||
| Sex (female:male) | 162:15 | 772:73 | 0.943 | ||
| CYC course (months) | 7.00 (5.00–12.00) | 6.00 (2.00–9.00) | 0.000 | 0.964 (0.876 to 1.060) | 0.446 |
| CYC accumulation (g) | 6.40 (4.45–9.00) | 4.80 (1.80–8.00) | 0.000 | 1.092 (0.964 to 1.236) | 0.166 |
| LN | 110 (62.15) | 463 (54.79) | 0.073 | 1.246 (0.826 to 1.878) | 0.294 |
| NPSLE | 24 (13.56) | 119 (14.08) | 0.855 | ||
| Leucopaenia | 28 (15.82) | 82 (9.70) | 0.017 | 2.266 (1.322 to 3.887) | 0.003* |
| Neutropaenia | 7 (3.95) | 13 (1.54) | 0.035 | 1.159 (0.258 to 5.199) | 0.847 |
| Lymphocytopaenia | 14 (7.91) | 28 (3.31) | 0.005 | 1.371 (0.565 to 3.327) | 0.485 |
| ILD | 16 (9.04) | 64 (7.57) | 0.509 | ||
| PAH | 15 (8.47) | 31 (3.67) | 0.005 | 2.756 (1.249 to 6.080) | 0.012* |
| Diabetes mellitus | 10 (5.65) | 31 (3.67) | 0.222 | 1.635 (0.633 to 4.224 | 0.310 |
| SLEDAI | 6.00 (2.00–10.00) | 6.00 (2.00–10.00) | 0.451 | ||
| CYC protocols | |||||
| SILD | 13.04% (66/506) | 86.96% (440/506) | 0.001 | 2.018 (1.315 to 3.097) | 0.001* |
| HD | 22.27% (57/256) | 77.73% (199/256) | |||
| Glucocorticoid pulse therapy | 20 (11.30) | 89 (10.53) | 0.764 | ||
| Glucocorticoid dose (mg) | 22.0 (10.0–40.0) | 20.0 (10.0–45.0) | 0.871 | ||
| Group 1 (without Pred) | 22 (12.43) | 128 (15.15) | |||
| Group 2 (≤15 mg/day) | 57 (32.20) | 278 (32.90) | 1.802 (0.865 to 3.753) | 0.116 | |
| Group 3 (>15 mg/day) | 98 (55.37) | 439 (51.95) | 2.220 (1.097 to 4.489) | 0.027* | |
Data were presented as median (IQR) or n count (percentage).
*P value <0.05. All p values less than 0.05 which is significant are in bold.
CYC, cyclophosphamide; HD, high dose; ILD, interstitial lung disease; IV-CYC, intravenous cyclophosphamide; LN, lupus nephritis; NPSLE, neuropsychiatric SLE; PAH, pulmonary arterial hypertension; Pred, prednisone; SILD, short interval lower dose; SLEDAI, Systemic Erythematosus Disease Activity Index.